Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GMDA - Gamida Cell Ltd.

Close
0.0327
-0.007   -22.324%

Share volume: 23,036,893
Last Updated: Fri 05 Apr 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 3.82%

PREVIOUS CLOSE
CHG
CHG%
$0.04
-0.01
-18.25%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 12%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.03
P/E Ratio 
0.00
DAY RANGE
$0.03 - $0.04
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
154.051 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Abigail L. Jenkins
Region: US
Website: gamida-cell.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Gamida Cell Ltd. develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk malignancies, as well as in Phase I/II clinical trials.

Recent news